Mylan To Pay SEC $30M For Misclassifying EpiPen
HERTFORDSHIRE, England — Mylan N.V. on July 29 said it has reached a $30 million agreement-in-principle to settle a U.S. Securities and Exchange Commission investigation into the misclassification of the EpiPen...To view the full article, register now.
Already a subscriber? Click here to view full article